Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
Top Cited Papers
Open Access
- 13 February 2020
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 117 (12), 6771-6776
- https://doi.org/10.1073/pnas.1922083117
Abstract
The continued emergence of Middle East Respiratory Syndrome (MERS) cases with a high case fatality rate stresses the need for the availability of effective antiviral treatments. Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy against Severe Acute Respiratory Syndrome (SARS)-CoV in a mouse model. Here, we tested the efficacy of prophylactic and therapeutic remdesivir treatment in a nonhuman primate model of MERS-CoV infection, the rhesus macaque. Prophylactic remdesivir treatment initiated 24 h prior to inoculation completely prevented MERS-CoV−induced clinical disease, strongly inhibited MERS-CoV replication in respiratory tissues, and prevented the formation of lung lesions. Therapeutic remdesivir treatment initiated 12 h postinoculation also provided a clear clinical benefit, with a reduction in clinical signs, reduced virus replication in the lungs, and decreased presence and severity of lung lesions. The data presented here support testing of the efficacy of remdesivir treatment in the context of a MERS clinical trial. It may also be considered for a wider range of coronaviruses, including the currently emerging novel coronavirus 2019-nCoV.Keywords
Funding Information
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (N/A)
This publication has 27 references indexed in Scilit:
- Late Ebola virus relapse causing meningoencephalitis: a case reportThe Lancet, 2016
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016
- Environmental Contamination and Viral Shedding in MERS Patients During MERS-CoV Outbreak in South KoreaClinical Infectious Diseases, 2015
- Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common MarmosetThe Journal of Infectious Diseases, 2015
- Infection with MERS-CoV Causes Lethal Pneumonia in the Common MarmosetPLoS Pathogens, 2014
- Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaquesProceedings of the National Academy of Sciences of the United States of America, 2013
- Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaquesNature Medicine, 2013
- Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive studyThe Lancet Infectious Diseases, 2013
- Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infectionsEurosurveillance, 2012
- Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis).2010